Key result
Erratum corrects funding details for the ROPAC pulmonary hypertension registry study.
Answers are grounded in this paper and cite their sources.
Funding correction does not alter conclusions; leaves open questions on sponsorship influence in this Level 5 ROPAC registry.
Karen Sliwa, Iris M. van Hagen, Werner Budts, Lorna Swan, Gianfranco Sinagra, Maryanne Caruana, Manuel Vazquez Blanco, Lodewijk J. Wagenaar, Mark R. Johnson, Gary Webb, Roger Hall, and Jolien W. Roos-Hesselink, on behalf of the ROPAC investigators Following the publication of Sliwa et al.1 some errors were identified in the companies listed in the Funding section, and the period of their involvement. The Funding section should read: “Since the start of EORP, the following companies have supported the programme: Abbott Vascular Int. (2011–2014), Amgen Cardiovascular (2009–2018), AstraZeneca (2014–2017), Bayer (2009–2018), Boehringer Ingelheim (2009–2016), Boston Scientific (2009–2012), The Bristol Myers Squibb and Pfizer Alliance (2011–2016), The Alliance Daiichi Sankyo Europe GmbH and Eli Lilly and Company (2011–2017), Gedeon Richter Plc. (2014–2017), Menarini Int. Op. (2009–2012), MSD-Merck & Co. (2011–2014), Novartis Pharma AG (2014–2017), ResMed (2014–2016), Sanofi (2009–2011), SERVIER (2009–2018).”
No takes yet. Share an insight, caveat, or question.
A 2017 study studied Pulmonary hypertension and pregnancy. This document is an erratum correcting the funding sources for the ROPAC registry study on pulmonary hypertension and pregnancy outcomes, containing no clinical results.
Synapse has enriched 10 related papers. Consider them for comparative context: